Viral Hepatitis (HCV, HBV, HDV/HBV)

Test anti-viral therapeutics with immediate relevance for human physiology in the PXB-mouse® and PXB-cells® models.

virus

Discover more about how PXB-mice and PXB-cells® are boosting the successes of ongoing viral hepatitis research

Resources Hub

The challenge

Due to the high species-specificity of hepatitis viruses, the success of your anti-viral therapeutics during clinical trials is highly influenced by the translational potential of the animal model used during preclinical research.

Gather highly translational insights into human outcomes during the preclinical testing of anti-viral therapeutics with our PXB-mouse® and PXB-cells® with human liver environments.

Our commercial scale production ensures that high quality PXB-mice are always available for your studies. A dedicated project management team will work with you on study design, feasibility, and execution — providing real-time solutions and regular reporting to ensure momentum is maintained throughout the study timeframe.

Viral hepatitis infection in vivo and in vitro with PXB-mice and PXB-cells®

Demonstrate antiviral efficacy in the development of your best-in-class therapeutics for viral hepatitis viruses, including hepatitis B, C and D virus, with unrivalled translational potential using PXB-mice and PXB-cells®.

We provide a full translational platform for viral hepatitis from in vitro, with our PXB-cells®, to in vivo, using PXB-mice. These products are ideal for viral hepatitis drug development as they support a viral infection comparable to humans and a human hepatocyte metabolism of compounds to increase confidence in your compound’s efficacy, tolerability, and safety.

mouse_icon

In vivo: PXB-mice

Chimeric mice with a humanized liver

Find out more

in_vitro_cells_icon

In vitro: PXB-cells®

Primary human hepatocytes freshly isolated from PXB-mice

Find out more

HBV inocula available and measurement parameters included in PhoenixBio study services

Inoculum genotypes available for HBV infection

Genotype

Subtype (Serotype)

Ae

adw

Bj

adw

C

adr

D

ayw

Genotypes Ae, Bj, C and D are available as HBV inocula for the in vivo HBV studies.

Serum assays specific for HBV

Parameter

HBV DNA

HBsAg

HBeAg

HBcrAg (HB core-related Ag)

Analysis of blood biochemistry such as h-ALT1, ALT, AST, and others can be provided as well.

Liver assays specific to HBV

Parameter

HBV DNA

cccDNA

HBsAg (via immunostaining)

HBcAg (via immunostaining)

DNA Polymerase Activity

Support all stages of hepatitis viral life cycles in PXB-mice and PXB-cells®

The viral-hepatitis infected PXB-mouse® is a powerful tool for evaluating the efficacy of anti-viral agents in a therapeutic or prophylactic approach. Model all stages of the Hepatitis B virus life cycle, including the formation of cccDNA, with the use of our chimeric mouse model with a highly humanized liver.

Our HBV-infected PXB-mouse® study services include the following in our Biosafety Level 2 (BSL2) facility:

  • Anti-viral efficacy (therapeutic or prophylactic)
  • Infectivity research
Contact us to learn more

Predict the human-specific toxicity and pharmacokinetics of your therapeutic agents

Get the most value out of your HBV research experiments with pharmacokinetic and toxicity assessment using our PXB-mouse® model and its humanized liver.

Confidently move forward to your viral hepatitis efficacy studies upon evaluation of your compound’s predicted human pharmacokinetics and human-specific toxicity. We offer study design strategies beginning with preliminary tolerability, pharmacokinetic, or toxicity studies prior to viral-hepatitis efficacy studies. Throughout viral-hepatitis efficacy studies, continue to monitor the pharmacokinetics and human-specific toxicity of your therapeutic agents to boost data collection and to realize the true potential of the PXB-mouse model.

Explore DMPK/Toxicity

Our clients typically add-on pharmacokinetic and toxicity assessments:

  • Before major HBV studies to confirm and predict tolerability, PK, or toxicity in a humanized liver environment.
  • In an HBV efficacy study to maximise their findings by adding PK or toxicity assessment to result in more comprehensive data.
Contact us

Find out how we help your viral hepatitis drug development projects

Contact us